8 At the end of the procedure, the eye surface was washed with balanced salt solution, two drops of levofloxacin were instilled and a bandage soft contact lens was placed. Neither intraoperative pachymetry nor slit-lamp examination was performed, because this was not part of the original treatment protocol. Focus of the UVA beam over the axial cornea was monitored constantly. During the procedure, riboflavin 0.1% drops were administered every 3 min if the patient reported discomfort, 1% tetracaine drops were administered. UVA exposure was performed for 30 min with 370 nm UVA radiation at 3 mW/cm 2 with a beam diameter of 8 mm. After a period of 10 min, the eye was exposed to ultraviolet A (UVA). Five drops of riboflavin 0.1% in dextran 20% (Streuli Pharma, Uznach, Switzerland) were instilled and then reapplied after 5 min. By using an epithelial spatula (Malosa Medical, Elland, UK), a 9 mm part of the central epithelium was removed. The procedure has been illustrated based on Wollensak’s procedure earlier on, tetracaine 1% and chloramphenicol 0.5% were instilled after informed consent was obtained. With the patient positioned under the operating microscope, an eyelid speculum was placed, and with a blunt spatula, the central 9 mm corneal epithelium was removed. 5 A comprehensive literature review of PubMed and Web of Science revealed that this investigation is the first one to study the long-term effectiveness of TICL on aberrations and contrast sensitivity in Iranian patients with stable keratoconus in January 2011. Nevertheless, issues that are debatable include the effects of TICL and the readaptation of the sensory system to diffraction-limited ocular optics after TICL implantation in patients with keratoconus. It is shown to be highly effective in preserving and improving best-corrected vision and preoperative values such as safety and stability.
The toric implantable collamer lens (TICL) is used in adults aged 21–40 years for correcting myopia (−3.0 to −23.0 D) and astigmatism (≤6 D) in refraction, with stable refraction and anterior chamber depth (ACD) ≥3 mm. The Visian ICL has been designed to be set completely inside the back chamber straight behind the iris and in front of the anterior capsule of the human crystalline lens, and when accurately situated, the lens works as a refractive component to progress vision. The Visian ICL has a plate haptic configuration with a central convex/concave optical zone and fuses a forward vault to minimise contact of the Visian ICL with the anterior capsule of the crystalline lens. The Visian ICL contains an ultraviolet (UV) absorber made from a UV-absorbing material.
5 The STAAR Surgical Visian ICL is an intraocular implant manufactured from a propriety hydroxylethylmethacrylate/porcine collagen-based biocompatible polymer material. 4 The implantation of a phakic intraocular lens into the posterior chamber, as demonstrated by clinical observations, can be a desirable alternative to visual defects resulting from refractive errors in the state of keratoconus. 2 3 Essential to each treatment is timing and applying the appropriate intervention method to each patient.
#Itrace posterior corneal aberrations series#
1 2 However, the exact mechanism by which it manifests in terms of progression, genetic heterogeneity and phenotypic diversity is not known, thereby resulting in a series of diverse diagnostic and treatment methods. It is a progressive, non-inflammatory and bilateral thinning of the centreof the cornea and is found to be the most widely seen type of corneal ectasia. Keratoconus is a cone-shaped protrusion of the cornea that is derived from the Greek words kerato (cornea) and konos (cone). Ketabi St, Shariati Ave, Tehran 1544914599, Iran farinaz_
0 kommentar(er)
